je.st
news
Tag: afrezza
MannKind Launches New Direction For Afrezza
2016-01-22 13:43:46| Biotech - Topix.net
MannKind Corporation's long-term CFO and newly chosen CEO, Matt Pfeffer, recently advanced a new blueprint at the J.P. Morgan Healthcare Conference, held two weeks ago, for the company's direction now that MannKind's partnership with Sanofi will be coming to an end.
Tags: direction
launches
afrezza
mannkind
A Pediatric Endocrinologist's View Of MannKind's Afrezza
2015-11-05 13:08:14| Biotech - Topix.net
There have been many investment analyst opinions expressed about the coming success or failure of MannKind Corporation's new inhaled insulin, Afrezza. Sanofi , MannKind's pharmaceutical marketing partner, has invested millions of dollars in up front licensing fees, milestone payments, and Afrezza related costs in marketing and promotion.
Danbury manufacturer Mannkind triples production despite slow sales of Afrezza
2015-08-01 10:39:52| Biotech - Topix.net
The annual stockholders meeting for Mannkind Corporation which recently gained approval from the FDA for a new form of insulin. On Thursday May 21, 2015, in Danbury, Conn.
Tags: sales
production
manufacturer
slow
Mannkind to triple Afrezza production
2015-04-27 23:45:31| Biotech - Topix.net
Executives with Mannkind are tripling their production capacity at their local manufacturing facility in the hopes that demand for their drug Afrezza will continue to increase in the coming months. Afrezza, the first inhalable and fast acting insulin, hit the market in February after several years in development by the drug company.
Tags: production
triple
afrezza
mannkind
One Internist's Glance At MannKind's Afrezza
2015-01-03 19:28:42| Biotech - Topix.net
I wanted to offer my assessment of the utility of Afrezza as a clinician, after doing a review of some of the available clinical data and evidence. A small meta-analysis of open-label randomized controlled trials from ClinicalTrials.gov indicates that Afrezza was associated with smaller reductions in A1C than control, and higher discontinuation rates.